Colorectal cancer represents the third most common cancer and about 20%are diagnosed with synchronous metastatic disease.From a historical point of view,surgery remains the mainstream treatment for resectable colorect...Colorectal cancer represents the third most common cancer and about 20%are diagnosed with synchronous metastatic disease.From a historical point of view,surgery remains the mainstream treatment for resectable colorectal liver metastases(CRLM).Furthermore,disease outcomes are improving due significant advances in systemic treatments and diagnostic methods.However,the optimal timing for neoadjuvant chemotherapy or upfront surgery for CRLM has not yet been established and remains an open question.Thus,patient selection combining image workouts,time of recurrence,positive lymph nodes,and molecular biomarkers can improve the decision-making process.Nevertheless,molecular profiling is rising as a promising field to be incorporated in the multimodal approach and guide patient selection and sequencing of treatment.Tumor biomakers,genetic profiling,and circulating tumor DNA have been used to offer as much personalized treatment as possible,based on the precision oncology concept of tailored care rather than a guideline-based therapy.This review article discusses the role of molecular pathology and biomarkers as prognostic and predictor factors in the diagnosis and treatment of resectable CRLM.展开更多
文摘Colorectal cancer represents the third most common cancer and about 20%are diagnosed with synchronous metastatic disease.From a historical point of view,surgery remains the mainstream treatment for resectable colorectal liver metastases(CRLM).Furthermore,disease outcomes are improving due significant advances in systemic treatments and diagnostic methods.However,the optimal timing for neoadjuvant chemotherapy or upfront surgery for CRLM has not yet been established and remains an open question.Thus,patient selection combining image workouts,time of recurrence,positive lymph nodes,and molecular biomarkers can improve the decision-making process.Nevertheless,molecular profiling is rising as a promising field to be incorporated in the multimodal approach and guide patient selection and sequencing of treatment.Tumor biomakers,genetic profiling,and circulating tumor DNA have been used to offer as much personalized treatment as possible,based on the precision oncology concept of tailored care rather than a guideline-based therapy.This review article discusses the role of molecular pathology and biomarkers as prognostic and predictor factors in the diagnosis and treatment of resectable CRLM.
